MARKET

ESLA

ESLA

Estrella Immunopharma
NASDAQ
1.300
-0.080
-5.80%
Pre Market: 1.300 0 0.00% 07:00 02/12 EST
OPEN
1.370
PREV CLOSE
1.380
HIGH
1.400
LOW
1.140
VOLUME
80
TURNOVER
0
52 WEEK HIGH
3.150
52 WEEK LOW
0.7301
MARKET CAP
54.64M
P/E (TTM)
-3.5173
1D
5D
1M
3M
1Y
5Y
1D
Estrella Immunopharma Is Maintained at Buy by D. Boral Capital
Dow Jones · 3d ago
Estrella Immunopharma Price Target Maintained With a $8.00/Share by D. Boral Capital
Dow Jones · 3d ago
D. Boral Capital Maintains Buy on Estrella Immunopharma, Maintains $8 Price Target
Benzinga · 3d ago
Estrella Immunopharma presents updated data on EB103
TipRanks · 3d ago
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 3d ago
Estrella Immunopharma Reports 100% Complete Response Rate for EB103 in Phase I B-cell NHL Trial
Reuters · 3d ago
Why STMicroelectronics Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Benzinga · 3d ago
Weekly Report: what happened at ESLA last week (0202-0206)?
Weekly Report · 3d ago
More
About ESLA
Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases. Its lead product candidate, EB103, utilizes Eureka's ARTEMIS technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. The Company is also developing EB104, which also utilizes Eureka's ARTEMIS technology to target not only CD19, but also CD22, a protein that, like CD19, is expressed on the surface of most B-cell malignancies. The Company is also collaborating with Imugene Limited and its product candidate, CF33-CD19t an oncolytic virus (CF33-CD19t), to research the use of EB103 in conjunction with CF33-CD19t to treat solid tumors. Its EB201 program, in preclinical development, is being explored as a potential therapeutic approach targeting Systemic Lupus Erythematosus (SLE).

Webull offers Estrella Immunopharma Inc stock information, including NASDAQ: ESLA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ESLA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ESLA stock methods without spending real money on the virtual paper trading platform.